Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. The company was founded in 2020 and is based in San Diego, California.
Company Website: https://www.revbiosciences.com